The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Bayer AG halted worldwide sales Monday of its anti-bleeding drug Trasylol at the request of U. S. and foreign health officials pending further analysis of a Canadian study that suggests it’s linked to a 50 percent higher risk of death than the other drugs in the clinical trial. The Food and Drug Administration asked the company to stop selling the drug, used to prevent excessive bleeding during heart bypass surgery, until it could receive and review further results from the study.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest